WILMINGTON, Mass.--(BUSINESS WIRE)--Cancer and anti-inflammatory drug developer Cellceutix (OTCBB: CTIX) completed a $400,000 9% Secured Convertible Debenture financing. The Debentures and concomitant interest come due December 1, 2009 and are convertible into the Company’s common stock at $1.50 a share.
